63E.F ONWARD MEDICAL BV EO -12

Healthcare Biotechnology Frankfurt Exchange
1.72 EUR
Close of Nov 11, 2026
1.72 4.88
Market cap
EUR 119M
P/E
-
P/B
1.69x
ROE
-75.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 63E.F undervalued?

Graham number

The Graham number of ONWARD MEDICAL BV EO -12 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONWARD MEDICAL BV EO -12 fundamental analysis

No fundamental analysis for ONWARD MEDICAL BV EO -12 yet.

ONWARD MEDICAL BV EO -12 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONWARD MEDICAL BV EO -12

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implan…

Full company profile